Trial Profile
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF). [Prior Title: SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia).]
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Tagraxofusp (Primary)
- Indications Chronic myelomonocytic leukaemia; Hypereosinophilic syndrome; Myelofibrosis; Myeloproliferative disorders; Systemic mastocytosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stemline Therapeutics
- 20 Mar 2023 Status changed from active, no longer recruiting to completed.
- 24 Jan 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.
- 24 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.